Precision medicine phase II study evaluating the efficacy of a double immunotherapy by durvalumab and tremelimumab combined with olaparib in patients with solid cancers and carriers of homologous recombination repair genes mutation in response or stable a
Fiche publication
Date publication
août 2020
Journal
BMC cancer
Auteurs
Membres identifiés du Cancéropôle Est :
Dr BERTAUT Aurélie, Pr GHIRINGHELLI François, Mme TRUNTZER Caroline, Dr LIMAGNE Emeric, Dr FUMET Jean-David, Dr THIBAUDIN Marion
Tous les auteurs :
Fumet JD, Limagne E, Thibaudin M, Truntzer C, Bertaut A, Rederstorff E, Ghiringhelli F
Lien Pubmed
Résumé
Tumors with deficient homologous repair are sensitive to PARP inhibitors such as olaparib which is known to have immunogenic properties. Durvalumab (D) is a human monoclonal antibody (mAb) which inhibits binding of programmed cell death ligand 1 (PD-L1) to its receptor. Tremelimumab (T) is a mAb directed against the cytotoxic T-lymphocyte-associated protein 4 (CTLA-4). This study is designed to evaluate the efficacy of combination of olaparib, durvalumab and tremelimumab in patients with a solid tumors with a mutation in homologous gene repair.
Mots clés
Durvalumab, Homologous repair, Immune checkpoint inhibitors, Olaparib, PARP inhibitors, Tremelilumab
Référence
BMC Cancer. 2020 Aug 10;20(1):748